These effects, along with a past report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,two help the notion of targeting ACKR3 as a novel approach to modulate the opioid program, which could open new therapeutic avenues for opioid-associated diso